The GHIT Fund announces an investment opportunity for the Target Research Platform
The GHIT Fund announces an investment opportunity for the Target Research Platform (TRP) in Partnership with the Wellcome Trust. The TRP investments are intentionally broad in potential scope and focus on new technologies and novel approaches.
TRP investments are intentionally broad in potential scope and focus on new technologies and novel approaches. Proposals must be within the project scope and investment eligibility below in order to be considered. The TRP is currently focused on technologies and approaches that address unmet or priority needs within malaria, tuberculosis, HIV/AIDS and Neglected Tropical Diseases listed in the GHIT Intent to Apply form.
MRC/AstraZeneca Centre for Lead Discovery
The MRC/AstraZeneca Centre for Lead Discovery (CLD) aims to support academic researchers in discovering potential starting points for small molecule therapeutic approaches with a clear line-of-sight to therapeutic use. The MRC/AZ Centre for Lead Discovery will form a unique cornerstone for academic and industrial drug discovery projects by supplying high throughput screening (HTS) infrastructure (NiCoLA-B).
Canada-UK Artificial Intelligence Initiative
The call aims to support innovative and cutting-edge interdisciplinary AI research that encourages the exploration of new interdisciplinary research methodologies, approaches and tools that cuts across at least two of the following research domains:
- social sciences and humanities;
- health and biomedical sciences; and
- natural sciences and engineering (including computational and/or mathematical sciences).
There is also a more comprehensive listing of grant funding here.
MMV has announced a call for drug discovery proposals
1. Compounds addressing the key priorities of the malaria eradication agenda
Novel families of molecules in the hit-to-lead or lead optimization stages are sought without G6PD deficiency liabilities that either:
Kill or reactivate hypnozoites for use as part of a P. vivax radical cure; or have activity against sexual stage V gametocytes and evidence of transmission blocking in SMFA.
2. Compounds having activity against asexual liver and/or blood stages
Novel chemical series with EC50<500nM and which have one or more of the following key features:
A known, novel mechanism of action; An inability to select resistant mutants in vitro; Activity at more than one life-cycle stage; A long half-life (ideally >4h in rodents) and confirmed in vivo efficacy. For advanced series, we are seeking novel compounds with, ideally, a predicted human half-life >100h and a predicted oral single human dose <500mg or an i.m. dose that can be administered in <1mL and sufficient for up to 3 months’ protection in humans.
3. Novel approaches for screening
To help identify new phenotypic and/ or target based hits, as well as confirm activity of MMV compounds on all human malaria asexual blood stages, new screening proposals are sought amongst the three categories below:
Validated Plasmodium target-based assays, ideally with evidence of target essentiality beyond asexual blood stages. Biological validation should be supported by a biological target based screening assay suited for identification of novel chemical series. Novel whole cell phenotypic screening paradigms to potentially identify new relevant chemistry. Asexual blood stage assays for vivax and ovale malaria.
Compounds for Target Identification
MMV also welcomes requests for support to investigate the mechanism of action of compounds:
Call for African proposals
Finally, MMV welcomes proposals from endemic region African scientists focused in the following priority areas:
Compounds with confirmed activity on any antimalarial life-cycle stage. Novel families of molecules with confirmed activity (EC50 < 10uM) and a medicinal chemistry plan that tackles any known or anticipated liability. Priority will be given to proposals that maximize use of local natural products.
Assay development and screening
Opportunity to apply for a share of up to £20 million to deliver game changing or disruptive innovations with significant potential for impact on the UK economy in partnership with Medicines Discovery Catapult.
Secure the funding you need to progress your projects towards commercialisation. Use our dedicated grant application team to ensure your submissions stand the best chance of success. Our experienced commercial and scientific teams have connections across industry, academia, finance, government, and research networks – we can help take your projects further towards commercial viability.
I've also compiled a page on Grant funded Research
Today Wellcome announced a new £250m not-for-profit fund: the Wellcome Leap Fund . The Leap Fund will accelerate discovery and innovation, with the aim of delivering breakthroughs over a five- to ten-year horizon.
"We want to take advantage of the surprising, left-field ideas that pose the question 'what if?' and support them in a new way that complements our existing funding structures."
Sounds like the aim is to support more high-risk research.
We don’t expect all projects to succeed, but we think the possibilities are incredibly exciting. And in taking some risks and backing at scale, we think we can deliver transformational developments that will improve people’s lives around the world
Wellcome have also recently announced the Open Research fund
Our new Open Research Fund supports innovative approaches that enable data, code or other research outputs to be discovered, accessed and reused
I've also compiled a page on Grant funded Research
An interesting review of economic benefits of medical research in the UK.
This briefing summarises a new peer-reviewed study estimating the economic returns generated by public and charitable investment in UK medical research.
Bottom line , Every £1 invested in medical research delivers a return equivalent to around 25p every year, for ever.
Studies have focused on cancer, cardiovascular, musculoskeletal disease and mental health research
I'm delighted to hear that CRUK and EPSRC are funding a scheme to encourage research collaborations between different disciplines.
Multidisciplinary Project Award supports collaborations between cancer researchers and scientists from engineering/physical science disciplines.
Applications should ideally include:
- a minimum of two PIs working in distinct scientific disciplines
- at least one PI working in cancer research at any career stage
- at least one PI from an engineering/physical science discipline at any career stage
Applications will be accepted from UK universities, research institutions, Cancer Research UK core-funded Institutes, medical schools and hospitals. The award is not required to be co-located and can be held across institutions in the UK, supporting roles from international and commercial organisations may also be included.
The book is the basis for "The Medici Effect," a term coined by Johansson and used throughout various industries to describe innovation that happens when disciplines and ideas intersect.
This might go some way towards correcting the bias against interdisciplinary research